Zentek and Triera Biosciences Secure $1.1 Million Government Contract

Zentek Ltd.'s subsidiary, Triera Biosciences Ltd., has been awarded a $1.1 million contract by the Government of Canada. The funding supports the testing of Triera's multivalent aptamer technology aimed at rapid drug discovery for avian influenza A(H5N1). This initiative aligns with Canada's focus on advancing the life sciences sector through Innovation, Science and Economic Development Canada's program.

The multivalent aptamer platform has previously shown potential by developing solutions effective against all variants of SARS-CoV-2. With this contract, Triera aims to develop a lead candidate within six months, in collaboration with agencies like Health Emergency Readiness Canada and Defence Research and Development Canada.

The project's success could lead to further government support and development opportunities for Triera's avian flu program, highlighting the importance of proactive outbreak responses.